Top-News
Pharmazeutika Belgien

Galapagos NV News

Aktie
WKN:  A0EAT9 ISIN:  BE0003818359 US-Symbol:  GLPGF
27,24 €
-0,16 €
-0,58%
11:04:19 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
65,90 Mio.
Marktkapitalisierung *
1,81 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.05.2024

Galapagos NV News

16.05.24 - GlobeNewswire
Galapagos creates new subscription right plans
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 ...
15.05.24 - GlobeNewswire
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centers Collaboration ...
02.05.24 - GlobeNewswire
Galapagos reports first quarter 2024 financial results  
Advanced potentially best-​in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunology Executed ...
30.04.24 - GlobeNewswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary ...
04.04.24 - GlobeNewswire
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-​Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) / ...
28.03.24 - GlobeNewswire
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
Publication of annual report for financial year 2023 Annual Shareholders’ Meeting resolutions include approval of revised Remuneration Policy and (re)appointment of Board ...
26.03.24 - GlobeNewswire
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors ...
22.02.24 - GlobeNewswire
Galapagos announces full year 2023 results and outlook for 2024
Full year 2023 key financials :
15.02.24 - GlobeNewswire
Galapagos presents at EBMT-EHA annual meeting 2024
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies
31.01.24 - GlobeNewswire
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its ...
04.01.24 - GlobeNewswire
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
Thermo Fisher Scientific to provide CAR-T manufacturing and kitting services for Galapagos’ point-​of-care CAR-T product candidate in the San Francisco area Agreement follows ...
03.01.24 - GlobeNewswire
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-​stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ ...
02.01.24 - GlobeNewswire
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, ...
19.12.23 - GlobeNewswire
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 ...
09.12.23 - GlobeNewswire
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe ...
07.12.23 - GlobeNewswire
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ...
02.11.23 - GlobeNewswire
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
First nine months 2023 key financials: Group revenues of €448.9 million Jyseleca® net sales of €82.1 million Cash and current financial investments of €3.8 billion at 30 September ...
30.10.23 - GlobeNewswire
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
Transaction would enable Galapagos to realize considerable annualized savings and accelerate its pipeline focused on developing transformational medicines Aims to preserve ...
19.09.23 - GlobeNewswire
Galapagos appoints Simon Sturge to its Board of Directors
Mechelen, Belgium; 1 9 September 2023, 22:01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 19 September 2023 , the Board of ...
28.08.23 - GlobeNewswire
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus  
GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor  GLPG3667 is currently in development for the treatment of inflammatory and ...

Newssuche

Videos

17.05.24 +9,45%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »